Project Grant R01NS148267
Award Date 8/15/26
Completion Date 7/31/31
Dollars Obligated $530K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Arizona, USA
Similar Awards
- The National Institute of Neurological Disorders and Stroke awarded the University of Arizona $1,764,771 on September 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to investigate the pathological relevance of TDP-43 interactions with translation machinery in neurodegeneration. The award funds research into TDP-43 proteinopathy, which is characterized by mislocalization of tar DNA-binding protein 43 from the nucleus to the...
- The National Institute of Neurological Disorders and Stroke awarded the University of Arizona $644,814 on July 6, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to investigate tau protein variants in FUS-mediated amyotrophic lateral sclerosis. The research focuses on identifying protective genetic mechanisms in unaffected mutation carriers who possess the ALS-linked FUS R521G mutation but remain disease-free into their 60s and...
- The National Institute on Aging awarded The Washington University $162,000 on March 1, 2026, under the Aging Research program (CFDA 93.866) to identify and characterize new therapy targets in TDP-43 proteinopathies. The award supports research into the mechanisms by which TDP-43 mislocalization results in neuronal death and aims to discover previously unidentified therapy targets that mediate this disease process. TDP-43 pathology is observed across multiple neurodegenerative diseases...
- Federal Project Grant Award Summary The National Institute on Aging (NIA) awarded $310,083 to the University of Arizona under the Aging Research program (CFDA 93.866) for a two-year project period from September 1, 2025, through August 31, 2027. This Project Grant supports biomedical research investigating the role of TMEM106B (Transmembrane Protein 106B) and mitochondrial dysfunction in frontotemporal lobar degeneration (FTLD) and other age-related dementias. The research aims to elucidate...
- The National Institute of Neurological Disorders and Stroke (NINDS) of the Department of Health and Human Services awarded Yale University $446,670 on May 6, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to develop and validate bi-functional helical peptides that inhibit TDP-43 aggregation. TDP-43 mislocalization and aggregation is central to amyotrophic lateral sclerosis (ALS), frontotemporal lobar degeneration with TDP-43...
- The Project Grant award of $404,058 from the National Institute on Aging (CFDA 93.866 - Aging Research) will fund research to identify novel small molecules that stabilize functional, multimeric forms of the TDP43 protein. The goal is to restore TDP43's native RNA binding and splicing regulation functions, which are impaired in frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), and other TDP43-related neurodegenerative diseases. The research will leverage high-throughput...
- The National Institute on Aging awarded the University of Pennsylvania $6.72 million on September 15, 2025, under the Aging Research program (CFDA 93.866) to develop short RNA therapeutics targeting TDP-43 proteinopathy across amyotrophic lateral sclerosis, frontotemporal dementia, Alzheimer's disease, limbic-predominant age-related TDP-43 encephalopathy, and chronic traumatic encephalopathy. The recipient will identify and characterize short oligonucleotides that engage the TDP-43 protein,...
- The National Institute on Aging awarded $423,592 to the University of Southern California on September 1, 2026, under the Aging Research program (CFDA 93.866) to investigate neurotransmitters as modulators of tau protein aggregation in Alzheimer's disease. The recipient is conducting structure-based research on monoaminergic neurotransmitters and their concentration-dependent effects on tau seeding, a disease-relevant mechanism by which fibrillar and oligomeric proteins catalyze aggregation. The...
- The National Institute on Aging awarded New York University $422,297 under the Aging Research program (CFDA 93.866) on February 15, 2026, to investigate mechanisms of dysregulated protein synthesis in human neurons carrying frontotemporal dementia–associated tau mutations. The project uses human induced pluripotent stem cell–derived neurons bearing FTD-associated tau mutations to model how pathogenic tau disrupts protein synthesis. In the first aim, researchers will determine the impact of...
- The National Institute of Neurological Disorders and Stroke awarded $551,888 to Massachusetts General Hospital on August 19, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to investigate the causes and consequences of tRNA ligation defects in neurodegeneration. The research examines how genomic GGC repeat expansions drive neurodegenerative diseases through polyglycine protein aggregation. The study biochemically characterized...